TheraRadar
← Back
Data updated: Jul 17, 2026

J AND J CONSUMER INC

Specialty
Pharmaceuticals

J AND J CONSUMER INC is a specialty pharmaceutical company with 7 FDA-approved products.

1976
Since
7
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Aug 25, 2026 — ZIIHERA (zanidatamab)

J AND J CONSUMER INC's Key Drugs

J AND J CONSUMER INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

J AND J CONSUMER INC's Recent FDA Approvals

New NDA/BLA approvals for J AND J CONSUMER INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

J AND J CONSUMER INC's Therapeutic Areas

Disease areas where J AND J CONSUMER INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

J AND J CONSUMER INC Pipeline Snapshot

Active clinical trials for J AND J CONSUMER INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling